Trafalgar International (GCAN) Cash & Current Investments (2017 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Cash & Current Investments of $1439.0 for Q1 2026, down 96.89% year-over-year from $46213.0 in Q1 2025, and up 76.56% quarter-over-quarter from $815.0 in Q4 2025.
Trafalgar International (GCAN) Cash & Current Investments (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $1439.0 for Q1 2026.
- In Q1 2026, Cash & Current Investments fell 96.89% year-over-year to $1439.0; the TTM figure through Mar 2026 stood at $1439.0 (down 96.89% YoY), while the FY2025 annual figure was $815.0, down 98.58% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $1439.0, up from $815.0 in the prior quarter.
- The five-year high for Cash & Current Investments was $311197.0 in Q2 2022, with the low at $815.0 in Q4 2025.
- The 5-year median for Cash & Current Investments is $62282.0 (2024), against an average of $108819.7.
- The sharpest annual moves came in 2023 and 2025: Cash & Current Investments declined 22.64% in 2023, then slumped 98.58% in 2025.
- Greater Cannabis Company's Cash & Current Investments stood at $270030.0 in 2022, then tumbled by 38.21% to $166859.0 in 2023, then slumped by 65.62% to $57368.0 in 2024, then plunged by 98.58% to $815.0 in 2025, then jumped by 76.56% to $1439.0 in 2026.
- Business Quant data shows GCAN's Cash & Current Investments at $1439.0 in Q1 2026, $815.0 in Q4 2025, and $21355.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,439.00 |
| Dec 31, 2025 | 815.00 |
| Sep 30, 2025 | 21,355.00 |
| Jun 30, 2025 | 26,712.00 |
| Mar 31, 2025 | 46,213.00 |
| Dec 31, 2024 | 57,368.00 |
| Sep 30, 2024 | 62,282.00 |
| Jun 30, 2024 | 80,316.00 |
| Mar 31, 2024 | 129,323.00 |
| Dec 31, 2023 | 166,859.00 |
| Jun 30, 2023 | 240,747.00 |
| Dec 31, 2022 | 270,030.00 |
| Jun 30, 2022 | 311,197.00 |
| Dec 31, 2021 | 377,520.00 |
| Sep 30, 2021 | 456,358.00 |
| Jun 30, 2021 | 528,930.00 |
| Mar 31, 2021 | 316,722.00 |
| Dec 31, 2020 | 112,953.00 |
| Sep 30, 2020 | 178,632.00 |
| Jun 30, 2020 | 228,518.00 |